This medicine has been shown to reduce blood glucose concentration, fasting plasma glucose concentrations, and postprandial glucose excursions
Strong IgG antibody responses to Borrelia burgdorferi glycolipids in patients with Lyme arthritis, a late manifestation of the infection
Moving from GLP-1 to insulin Conversely, some patients on GLP-1 therapy may eventually need insulin if their Type 2 diabetes progresses and beta cell function declines further
In a January 2024 update, the FDA stated that its preliminary evaluation has not found evidence that GLP-1 RAs cause suicidal thoughts or actions, based on available clinical trial data and adverse event reports (FDA Drug Safety Communication, 2024)
Obesity treatment The most obvious application is as an anti-obesity drug
Start by ensuring the pharmacy is a licensed 503A facility and that they will be compounding the medication for a specific patient